MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development
The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for ...
Tag: VEGF
Exonate first-in-class eye drop Phase Ib/IIa trial data demonstrate safety and biological activity in treatment of diabetic retinopathy and diabetic macular oedema
Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data ...
Age-related macular degeneration reported to confer higher risk of severe SARS-CoV-2 infection
Recent evidence has emerged to suggest that age-related macular degeneration (AMD) is a clinical risk factor for increased risk for ...
Study proposes a new concept for treating COVID-19 associated weight loss
Losing too much weight when infected with COVID-19 has been linked to worse outcomes. Now, researchers at Karolinska Institutet in ...
Study shows how dietary saturated/trans fats promote liver tumorigenesis
In light of the recent pandemic, people across the globe are increasingly becoming aware of the importance of consistent high-quality ...
A stepped regimen of anti-VEFG drugs leads to good vision outcomes in diabetic macular edema
Clinical trial results from the DRCR Retina Network suggest that a specific step strategy, in which patients with diabetic macular ...
Molecular target discovery opens new pathways for developing effective anti-angiogenic cancer therapy
Researchers with The Ohio State College Complete Cancer Middle – Arthur G. James Cancer Hospital and Richard J. Solove Analysis ...
